Oncology Convergence Inc.

Oncology Convergence Inc. Oncology Convergence, Inc. (OCI) is a group of dedicated oncology professionals whose sole purpose i

Your oncology department could be generating $1M+ in 340B margin per physician—but are you actually capturing it? 🏥💡Onco...
11/17/2025

Your oncology department could be generating $1M+ in 340B margin per physician—but are you actually capturing it? 🏥💡

Oncology drives 41% of all 340B drug purchases, with potential margins up to 45% of reimbursement. Yet many DSH hospitals leave significant value uncaptured due to revenue cycle inefficiencies.

This isn't discretionary income. These dollars fund uncompensated care, shore up unprofitable service lines, and power your community health mission.

Oncology Convergence specializes in closing 340B revenue gaps through comprehensive audits and optimized billing processes designed specifically for oncology.

✅ Stop the leak. Start capturing your full 340B potential: https://bit.ly/3BKDOpL

Let me share a statistic that should get every DSH hospital CFO's attention:Each oncologist in your program could be gen...
11/17/2025

Let me share a statistic that should get every DSH hospital CFO's attention:

Each oncologist in your program could be generating over $1 million in 340B margin. 🏥

Sound too good to be true? It's actually a commonly cited benchmark in the industry, and here's why the math works:

Oncology is the powerhouse of 340B programs, accounting for 41% of all 340B drug purchases nationwide. With margins that can hit 45% of total reimbursement, the financial impact is massive.

But here's what keeps me up at night (and probably you too): How many hospitals are actually capturing that full potential?

340B oncology billing is notoriously complex. Compliance requirements are strict. Documentation must be airtight. One small process gap, and you're watching significant margin slip away—margin that funds uncompensated care, supports essential services, and enables your mission.

The good news? With the right expertise and systems, optimizing your 340B oncology revenue cycle is absolutely achievable.

At Oncology Convergence, this is literally all we do. We've helped countless hospital-based oncology practices identify profit leaks, implement compliant processes, and maximize their 340B capture. Our team has deep oncology expertise (15+ years on average) and proprietary software that finds the revenue you're missing.

Is your 340B program performing at its peak? Let's find out together: https://bit.ly/3Msnn3D

The 340B program is a double-edged sword for DSH hospitals. 💰⚖️The Reward: Median annual savings of $8.9 million that fu...
11/15/2025

The 340B program is a double-edged sword for DSH hospitals. 💰⚖️

The Reward: Median annual savings of $8.9 million that fund your mission-critical services.

The Risk: Manufacturer repayments, severe penalties, and potential program expulsion if compliance falters.

Your oncology service line is both your biggest 340B value driver AND your largest compliance exposure. With oncology accounting for 41% of all 340B purchases, getting it right isn't optional.

Oncology Convergence helps you balance the duality—maximizing revenue while mitigating risk through expert-led revenue cycle management tailored to 340B complexities.

📞 Ready to strengthen your 340B strategy? https://bit.ly/3BKDOpL

Your hospital's 340B oncology program could be underperforming by millions.Consider this: Industry data shows each oncol...
11/13/2025

Your hospital's 340B oncology program could be underperforming by millions.

Consider this: Industry data shows each oncologist at a DSH hospital can generate over $1 million in 340B margin annually. Oncology accounts for 41% of all 340B drug purchases, with margins reaching 45% of total reimbursement.

Now ask yourself: Are you capturing that full potential?

If the answer is "I'm not sure," you need to know this:

Every dollar of uncaptured 340B margin is a dollar that can't fund:
→ Uncompensated care for vulnerable patients
→ Essential but underfunded service lines
→ Community health initiatives that define your mission

The stakes are too high to leave this to chance.

340B oncology revenue cycles are among the most complex in healthcare. Compliance is non-negotiable. Documentation requirements are rigorous. And the billing landscape changes constantly. Without specialized expertise, even well-run programs leave significant revenue on the table.

Oncology Convergence exists to solve exactly this problem. We combine deep oncology billing expertise, proprietary audit technology, and proven process improvements to help hospital-based oncology practices maximize compliant 340B revenue capture.

Our clients don't wonder if they're optimizing their 340B program—they know they are.

Stop leaving critical funding on the table. Schedule a revenue cycle audit today: https://bit.ly/3Msnn3D

Is each of your oncologists generating over $1 million in 340B margin for your hospital? 🏥It's not just a possibility; i...
11/11/2025

Is each of your oncologists generating over $1 million in 340B margin for your hospital? 🏥

It's not just a possibility; it's a commonly cited industry statistic for DSH hospitals. Oncology services are the primary engine of 340B savings, accounting for an incredible 41% of all 340B drug purchases. The margin on these therapies can be as high as 45% of the total reimbursement collected.


This isn't just revenue—it's the financial lifeline that funds uncompensated care, supports underfunded service lines, and allows you to fulfill your community mission.


But is your revenue cycle optimized to capture this value compliantly?

At Oncology Convergence, we specialize in navigating the complexities of the 340B oncology revenue cycle to ensure you don't leave this critical funding on the table.

On this Veterans Day, Oncology Convergence pauses to honor and thank all the brave individuals who have worn the uniform...
11/11/2025

On this Veterans Day, Oncology Convergence pauses to honor and thank all the brave individuals who have worn the uniform of our nation.

Your selfless service, courage, and sacrifice have protected our freedoms and kept us safe. We are profoundly grateful for your commitment.

To all veterans and your families: Thank you.

Is each of your oncologists generating over $1 million in 340B margin for your hospital? 🏥For DSH hospitals, this isn't ...
11/10/2025

Is each of your oncologists generating over $1 million in 340B margin for your hospital? 🏥

For DSH hospitals, this isn't aspirational—it's an industry benchmark. Oncology services drive 41% of all 340B drug purchases, with margins reaching up to 45% of total reimbursement.

This revenue funds uncompensated care, supports struggling service lines, and enables your community mission. But only if your revenue cycle is optimized to capture it compliantly.

At Oncology Convergence, we specialize in maximizing 340B oncology value while maintaining strict compliance. Don't leave critical funding on the table.

👉 Let's optimize your 340B revenue cycle: https://bit.ly/3BKDOpL

11/09/2025

In order to improve the financial performance of your oncology department or practice, you need to do an oncology revenue cycle assessment. Oncology Convergence can help you find, fix and fund oncology revenue cycle problems so you can achieve success.

Get the details about our Oncology Revenue Recovery (ORR)™ here:
https://bit.ly/3khgvaq

Walking the 340B tightrope? One misstep can cost millions. 🎪DSH hospitals save a median of $8.9 million annually through...
11/06/2025

Walking the 340B tightrope? One misstep can cost millions. 🎪

DSH hospitals save a median of $8.9 million annually through 340B—but the program's complexity creates serious exposure:

• Manufacturer repayments
• Financial penalties
• Program expulsion

With oncology representing 41% of 340B purchases and margins reaching 45% of reimbursement, your oncology revenue cycle is both your greatest opportunity and your highest-risk area.

You need more than compliance—you need optimization. Oncology Convergence brings specialized expertise to navigate 340B complexities while maximizing your financial performance.

🎯 Balance risk and reward with confidence: https://bit.ly/3BKDOpL

🎯 DSH Hospitals: Your 340B Oncology Program Deserves BetterThe 340B program is too important to mismanage. The financial...
11/06/2025

🎯 DSH Hospitals: Your 340B Oncology Program Deserves Better

The 340B program is too important to mismanage. The financial stakes in oncology are too high. The compliance risks are too severe.

DSH hospitals face an impossible choice: master the intersection of oncology billing and 340B compliance, or accept suboptimal performance in their most critical revenue stream.

Here's the reality: Your team is stretched thin managing patient care while navigating:

• Complex oncology coding and dosing calculations
• State-specific 340B billing requirements
• Split-billing software configuration and maintenance
• HRSA audit preparation and response protocols
• Payer denial management and appeals processes

There's a better way forward.

Your mission is patient care. Your financial sustainability depends on 340B optimization. The expertise to manage both successfully doesn't have to be developed internally—it can be accessed through strategic partnership.

At Oncology Convergence, we specialize in the convergence of people, process, and technology. With decades of oncology revenue cycle experience and deep 340B expertise, we help DSH hospitals transform their 340B oncology programs from compliance burdens into strategic advantages.

Ready to optimize your 340B oncology revenue cycle?

📩 Learn more at oncologyconvergence.com/contact-us

11/06/2025

📈 FACT: Oncology practices are uniquely complex. Your billing partner should be too.

While other billing companies dabble in multiple specialties, Oncology Convergence focuses on one thing: maximizing revenue for oncology practices. Our results speak for themselves:

Collection rates up to 99.8%
Specialized drug inventory management
Expert handling of denial appeals
Deep understanding of payer requirements
Your practice is worth protecting. Partner with the experts who understand your unique challenges.

Book a call to learn more: https://bit.ly/3Msnn3D

For DSH hospitals, outsourcing 340B oncology billing isn't an expense—it's risk mitigation and revenue optimization.Cons...
11/05/2025

For DSH hospitals, outsourcing 340B oncology billing isn't an expense—it's risk mitigation and revenue optimization.

Consider the ROI calculation:

• Median 340B savings for DSH hospitals: $8.9 million annually
• Oncology represents the largest savings opportunity within 340B
• HRSA audit repayments can reach millions for systemic violations
• Expert billing services prevent claim denials and optimize collections

The value proposition extends beyond billing:

• Risk mitigation - Specialized compliance expertise prevents costly violations
• Revenue optimization - Expert coders maximize legitimate reimbursement
• Strategic focus - Internal teams concentrate on clinical excellence

When oncology generates the highest 340B margins but carries the greatest compliance risk, specialized management becomes a strategic imperative.

Address

8950 S 52nd Street #101
Tempe, AZ
85284

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+16024419520

Alerts

Be the first to know and let us send you an email when Oncology Convergence Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Oncology Convergence Inc.:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

We Help You Work Smarter

The OCI team focuses on oncology reimbursement, management, and technology. Oncology Convergence, Inc. (OCI) has one of the most specialized teams in the industry.

OCI combines clinical and financial experience to assist and guide oncology practices to maximize profits without sacrificing patient care, time or compliance.

Our managers and staff have an average of 15 years of experience in Radiation Oncology, Medical Oncology, Gynecologic Oncology, Pediatric Oncology, Clinical Research and Diagnostic Imaging.

OCI’s professionals have many years experience in oncology billing and revenue management. We understand how to optimally guide a practice to the highest revenue results. With our experience and knowledge, we can better advise our revenue management clients than a typical back end billing company can. With regular reports and a real-time client portal with up-to-date data, your organization is never left wondering about when a claim has been processed and paid.